NCT07398937RecruitingPhase 2
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
A Randomized, Open-label, Multicenter Phase II Clinical Trial Evaluating the Efficacy and Safety of Serplulimab Combined With Chemotherapy Versus Nivolumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIa Squamous NSCLC.
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
This trial is a randomized, controlled, multicenter, open-label study, planning to enroll 116 subjects with resectable stage II-IIIa squamous NSCLC confirmed by histopathology or cytology, aiming to evaluate the efficacy and safety of serplulimab compared to nivolumab combined with chemotherapy in neoadjuvant therapy. This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1036.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- First submitted
- 3 Feb 2026
- Start date
- 5 Feb 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Fudan University
- Diseases
- Lung cancer
- NCT number
- NCT07398937
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 116
- From 5 Feb 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other pathological histological types of non-small cell lung cancer subjects, including adenocarcinoma subjects, squamous-adenocarcinoma mixed cancer subjects, and NSCLC containing components of small cell lung cancer and neuroendocrine carcinoma.
Lab values
- EGFR sensitivity mutation or ALK, ROS1 gene rearrangement;
- Known severe allergy to any components of carboplatin/albumin paclitaxel and other drugs;
Other
- Central nervous system (CNS) or leptomeningeal metastases confirmed by imaging or pathology
Who the study is looking for
- Age ≥ 18 years and ≤ 75 years at time of study entry.
- The International Federation of Gynecology and Obstetrics (FIGO) 2018 Stages II-IIIA squamous non-small cell lung cancer confirmed by histopathology or cytology.
- The patient with stage II-IIIA squamous non-small cell lung cancer confirmed by histopathology or cytology;
- Able to tolerate complete lung cancer resection;
- WHO/ECOG performance status of 0 or 1.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.